title: Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.
abstract: OBJECTIVE
  To describe the response rate (RR), progression-free survival (PFS), and toxicity profile of combination gemcitabine, platinum, and bevacizumab (GPB) for the treatment of recurrent epithelial ovarian cancer (EOC).
  
  
  METHODS
  A chart review of all patients with recurrent EOC who were treated with D1, D15 GPB in a 28-day cycle at a single institution was performed. Standard doses were gemcitabine 1000 mg/m(2), cisplatin 30 mg/m(2) or carboplatin AUC 3, and bevacizumab 10 mg/kg. All patients were analyzed for toxicity. RR and PFS were assessed in all patients who received at least 2 cycles of GPB.
  
  
  RESULTS
  Thirty-five patients were identified, and 33 received at least 2 cycles of GPB. The majority of patients (80%) were platinum sensitive. Patients received a median of 6 cycles of GPB (range 1-24). Sixteen patients (48%) had a complete response (CR), and 10 patients (30%) had a partial response (PR), for a total RR of 78%. An additional 5 patients (15%) had stable disease, and only 2 (6%) patients had progressive disease. The median overall PFS was 12 months (95% CI 7-15), with a median follow-up time of 10 months (2-22). Two patients (6%) had bowel perforations, and both survived. Hematologic toxicities were most common, with 29% and 14% of patients experiencing grade 3 or 4 neutropenia and thrombocytopenia respectively.
  
  
  CONCLUSIONS
  The combination of GPB demonstrated excellent efficacy for the treatment of recurrent EOC. However, serious toxicities occurred, and the safety profile of this combination requires further study.
authors.affiliation: Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University College of Medicine, Columbus, OH, USA.
authors.forename: Debra L
authors.initials: DL
authors.lastname: Richardson
authors.forename: Floor J
authors.initials: FJ
authors.lastname: Backes
authors.forename: Leigh G
authors.initials: LG
authors.lastname: Seamon
authors.forename: Vanna
authors.initials: V
authors.lastname: Zanagnolo
authors.forename: David M
authors.initials: DM
authors.lastname: O'Malley
authors.forename: David E
authors.initials: DE
authors.lastname: Cohn
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Fowler
authors.forename: Larry J
authors.initials: LJ
authors.lastname: Copeland
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D018394:CA-125 Antigen / Q000378:metabolism; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D012189:Retrospective Studies; D000093542:Gemcitabine
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018394:CA-125 Antigen; D003841:Deoxycytidine; D000068258:Bevacizumab; D016190:Carboplatin; D002945:Cisplatin; D000093542:Gemcitabine